ASPREVA LUPUS MANAGEMENT STUDY PDF

PDF | On Jan 1, , E.M. Ginzler and others published Aspreva Lupus Management Study (ALMS): Maintenance Results. [abstract]. *Members of the Aspreva Lupus Manage- ment Study (ALMS) Group are listed in the Supplementary Appendix, available at The study group underwent repeat randomization in a ratio. A total of patients were randomly assigned to maintenance treatment ( to a renal response to treatment and in preventing relapse in patients with lupus (Funded by Vifor Pharma [formerly Aspreva]; ALMS number, NCT).

Author: Kajilkree Togal
Country: Senegal
Language: English (Spanish)
Genre: Education
Published (Last): 23 November 2006
Pages: 252
PDF File Size: 20.20 Mb
ePub File Size: 2.37 Mb
ISBN: 502-2-36409-320-6
Downloads: 30980
Price: Free* [*Free Regsitration Required]
Uploader: Tygoramar

Systematic review and meta-analysis of randomised studu and cohort studies of mycophenolate mofetil in lupus nephritis. Randomization and Interventions Patients were randomly assigned 1: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Secondary end points were also similar between treatment groups. J Am Soc Nephrol A meta-analysis of randomized controlled trials.

Controlled trial of prednisone and cytotoxic drugs. Several studies have compared cyclophosphamide and MMF, generally finding that MMF is equivalent to cyclophosphamide in terms of efficacy, with a lower risk of ovarian failure. Secondary end points included complete renal remission, systemic disease activity and damage, and safety. Open in a dtudy window.

Michael Neuwelt, MD, Inc. For both treatments, the most common AEs were infections and gastrointestinal disorders, asprevw in approximately two thirds of patients.

Overall, we did not detect a significantly different response rate between the two groups: IVC was given in monthly pulses of 0. Author information Article notes Copyright and License information Disclaimer. Although most patients in both treatment groups experienced clinical improvement, the study did not meet its managemebt objective of showing that MMF was superior to IVC as induction treatment for lupus nephritis.

  ELECTROLUX ESL 499 PDF

Navigation menu Personal tools Create account Log in. During the study, any drugs affecting the angiotensin system were taken at stable dosage. Although meta-analyses of smaller studies 17 — 19 have suggested that more patients respond to MMF than to IVC, results from the large and racially diverse population of this study indicate that these drugs in combination with prednisone have similar efficacy in short-term induction therapy.

Odds ratios were calculated using logistic regression models for response. Please review our privacy policy. Supplementary Material [Supplemental Data] Click here to view.

At the end of the week induction period, renal responses were observed in Patients who were aged 12 to 75 yr and had a diagnosis of SLE by American College of Rheumatology criteria 33 were enrolled between July 27,and October 6, The median dosage was calculated for patients in the MMF group as 2. Data from the ALMS study have been published in abstract form at the following congresses: However, it has been suggested by the authors and others that a longer induction period may better distinguish the two treatment arms.

Newer drugs for the treatment of lupus nephritis. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. Retrieved from ” http: Here, we report the comparison of MMF and IVC as induction treatment for active lupus nephritis in a multinational, two-phase induction and maintenance study.

Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis.

Impact of the ALMS and MAINTAIN trials on the management of lupus nephritis.

managfment The objective of this study was to test whether MMF was superior to IVC in the primary end point, namely the proportion of patients responding to treatment.

  ASYMMETRIC INFORMATION IN FINANCIAL MARKETS BEBCZUK PDF

The institutional review boards at all participating centers approved the protocol, and all patients provided written informed consent. Clin J Am Soc Nephrol 2: During 24 wk, increased malignancy risk or gonadal toxicity with IVC was not expected.

Complete remission rates were low for both treatments in comparison with previous randomized studies in Hong Kong and the United States, although the definitions of remission vary between studies. Any patient who did not complete the wk induction phase for any reason or who received pulse methylprednisolone therapy for managemejt renal or extrarenal flare was classified as a nonresponder. asprsva

ALMS – Wiki Journal Club

Views Read View source View history. Mycophenolate mofetil for induction therapy of lupus nephritis: An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a year period. Waldman M, Appel GB: Oral MMF was given twice daily, titrated from 0.

lupua Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: Appel GB, et al. Six randomly assigned patients one in the MMF group and five in the IVC group were excluded from the safety analysis because they received no study drug. For patients in the IVC group and for patients in each of the self-reported racial groups, the median number of doses was 6.

VPN